Betsy Morrow

1.1k total citations
18 papers, 497 citations indexed

About

Betsy Morrow is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Betsy Morrow has authored 18 papers receiving a total of 497 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Betsy Morrow's work include Occupational and environmental lung diseases (11 papers), PARP inhibition in cancer therapy (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Betsy Morrow is often cited by papers focused on Occupational and environmental lung diseases (11 papers), PARP inhibition in cancer therapy (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Betsy Morrow collaborates with scholars based in United States, Italy and South Korea. Betsy Morrow's co-authors include Anish Thomas, Raffit Hassan, Seth M. Steinberg, Jingli Zhang, Arun Rajan, Manjistha Sengupta, Swati Khanna, Idrees Mian, Trung C. Pham and Christopher Lau and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Clinical Cancer Research.

In The Last Decade

Betsy Morrow

18 papers receiving 490 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Betsy Morrow United States 11 211 180 122 93 60 18 497
H Sasaki Japan 10 75 0.4× 122 0.7× 136 1.1× 109 1.2× 18 0.3× 19 346
Ignacio I. Wistuba United States 6 83 0.4× 206 1.1× 241 2.0× 67 0.7× 41 0.7× 7 513
Luisa Circelli Italy 14 45 0.2× 220 1.2× 112 0.9× 75 0.8× 8 0.1× 23 433
Norishige Iizuka Japan 12 131 0.6× 101 0.6× 157 1.3× 32 0.3× 17 0.3× 27 399
Nicholas P. Schaub United States 8 48 0.2× 222 1.2× 66 0.5× 34 0.4× 13 0.2× 8 403
Carla Pecchioni Italy 10 50 0.2× 159 0.9× 107 0.9× 67 0.7× 7 0.1× 12 384
Alexandra M. Haugh United States 10 180 0.9× 461 2.6× 167 1.4× 111 1.2× 11 0.2× 16 625
P S Hasleton United Kingdom 9 280 1.3× 137 0.8× 78 0.6× 27 0.3× 41 0.7× 11 404
Theresa Foster United States 6 86 0.4× 189 1.1× 139 1.1× 26 0.3× 7 0.1× 8 389

Countries citing papers authored by Betsy Morrow

Since Specialization
Citations

This map shows the geographic impact of Betsy Morrow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Betsy Morrow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Betsy Morrow more than expected).

Fields of papers citing papers by Betsy Morrow

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Betsy Morrow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Betsy Morrow. The network helps show where Betsy Morrow may publish in the future.

Co-authorship network of co-authors of Betsy Morrow

This figure shows the co-authorship network connecting the top 25 collaborators of Betsy Morrow. A scholar is included among the top collaborators of Betsy Morrow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Betsy Morrow. Betsy Morrow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Nair, Nishanth Ulhas, Qun Jiang, Jun S. Wei, et al.. (2023). Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesothelioma. Cell Reports Medicine. 4(2). 100938–100938. 11 indexed citations
2.
Ghafoor, Azam, Idrees Mian, Betsy Morrow, et al.. (2021). Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene. JTO Clinical and Research Reports. 2(10). 100231–100231. 33 indexed citations
3.
Jiang, Qun, Azam Ghafoor, Idrees Mian, et al.. (2020). Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti–PD-1 antibody in patients with mesothelioma and mouse tumor models. Science Translational Medicine. 12(550). 35 indexed citations
4.
Khanal, Manakamana, Junko Murai, Jingli Zhang, et al.. (2020). Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression. Journal of Thoracic Oncology. 15(5). 843–859. 54 indexed citations
5.
Hassan, Raffit, Idrees Mian, Emerson Padiernos, et al.. (2020). Phase II study of olaparib in malignant mesothelioma (MM) to correlate efficacy with germline and somatic mutations in DNA repair genes.. Journal of Clinical Oncology. 38(15_suppl). 9054–9054. 12 indexed citations
6.
Khanal, Manakamana, Junko Murai, Qun Jiang, et al.. (2019). MA12.03 PARP Inhibitor Sensitivity Does Not Depend on BAP1 but Is Enhanced by Temozolomide in MGMT Deficient Human Mesothelioma Cells. Journal of Thoracic Oncology. 14(10). S296–S296. 1 indexed citations
7.
Mian, Idrees, Zied Abdullaev, Betsy Morrow, et al.. (2019). Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma. Journal of Thoracic Oncology. 15(3). 457–461. 23 indexed citations
8.
Jiang, Qun, Azam Ghafoor, Idrees Mian, et al.. (2019). MA12.11 Anti-Tumor Efficacy of Mesothelin Targeted Immunotoxin LMB-100 Plus Pembrolizumab in Mesothelioma Patients and Mouse Models. Journal of Thoracic Oncology. 14(10). S299–S300. 1 indexed citations
9.
Komiya, Takefumi, Gideon M. Blumenthal, Marc Ballas, et al.. (2019). A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN. The Oncologist. 24(12). 1510–e1265. 43 indexed citations
10.
Khanna, Swati, Francis Mussai, Anish Thomas, et al.. (2018). Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients. Clinical Cancer Research. 24(12). 2859–2872. 43 indexed citations
11.
Yu, Yunkai, Bríd M. Ryan, Anish Thomas, et al.. (2018). Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer. The Journal of Applied Laboratory Medicine. 3(2). 166–177. 9 indexed citations
12.
Hassan, Raffit, Betsy Morrow, Tom Walsh, et al.. (2018). Inherited predisposition to malignant mesothelioma (MM) due to mutations in DNA repair genes.. Journal of Clinical Oncology. 36(15_suppl). 8504–8504. 4 indexed citations
13.
Khanna, Swati, Anish Thomas, Daniel Abate‐Daga, et al.. (2016). Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti–PD-L1 Antibody Avelumab. Journal of Thoracic Oncology. 11(11). 1993–2005. 78 indexed citations
14.
Wang, Yisong, Anish Thomas, Christopher Lau, et al.. (2014). Mutations of epigenetic regulatory genes are common in thymic carcinomas. Scientific Reports. 4(1). 98 indexed citations
15.
Blumenthal, Gideon M., Joell J. Gills, Marc Ballas, et al.. (2014). A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors. Oncotarget. 5(18). 8161–8172. 30 indexed citations
16.
Giaccone, Giuseppe, Ariel López-Chávez, Anish Thomas, et al.. (2013). Custom (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies) trial.. Journal of Clinical Oncology. 31(15_suppl). 7513–7513. 5 indexed citations
17.
Komiya, Takefumi, Gideon M. Blumenthal, Marc Ballas, et al.. (2013). A pilot study of sirolimus (S) in subjects with Cowden syndrome (CS) with germ-line mutations in PTEN.. Journal of Clinical Oncology. 31(15_suppl). 2532–2532. 7 indexed citations
18.
Zhang, Chunyu, Abdel Elkahloun, Hongling Liao, et al.. (2011). Expression Signatures of the Lipid-Based Akt Inhibitors Phosphatidylinositol Ether Lipid Analogues in NSCLC Cells. Molecular Cancer Therapeutics. 10(7). 1137–1148. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H Sasaki Breakdown of academic impact, for papers by Ignacio I. Wistuba Breakdown of academic impact, for papers by Luisa Circelli Breakdown of academic impact, for papers by Norishige Iizuka Breakdown of academic impact, for papers by Nicholas P. Schaub Breakdown of academic impact, for papers by Carla Pecchioni Breakdown of academic impact, for papers by Alexandra M. Haugh Breakdown of academic impact, for papers by P S Hasleton Breakdown of academic impact, for papers by Theresa Foster
Rankless by CCL
2026